India Says WHO’s Info ‘Inadequate’ to Probe Cough Syrup-Linked Gambia Deaths, Seeks More Details
News 18India has sought more details from the World Health Organization to continue with its probe into the death of 66 children in The Gambia allegedly due to four made-in-India cough syrups. In an email response, Drugs Controller General of India V G Somani on Saturday said the Union Ministry of Health has constituted a committee of technical experts to examine and analyse the details of the adverse event reports and all related details shared by or to be shared by WHO and to recommend follow up action. Mentioning the observations, Dr Somani said, “The clinical features and the treatment received by the children as shared by WHO so far are inadequate to determine the aetiology.” He said that the details of initial illness, sign and symptoms, duration of anura in the cases, results of laboratory investigations conducted including various markers and parameters, specific investigations for diethylene glycol and ethylene glycol on critical samples of the patients, treatment received before and after hospitalization at the tertiary hospital in Gambia, treatment received before and after acute kidney injury was suspected and reasons thereof, names and brands of the drug formulations used in the treatment before and after hospitalization, their manufacturers, their expiry other relevant information in each of the cases, are necessary, news agency PTI reported. The Union Health Ministry on Wednesday formed the four-member panel of experts to examine the details and adverse event reports received from the WHO on the deaths of 66 children in Gambia being linked potentially to the four cough syrups made by the Sonipat unit of Maiden Pharmaceuticals.